Vivos Therapeutics, Inc. VVOS shares are trading lower Tuesday. The company filed a prospectus related to the resale of up to 1.73 million shares of common stock by selling shareholders.
The Details:
Vivos said that if the warrants held by the selling stockholder are exercised in full for cash, the company would receive approximately $8.4 million.
The company announced receipt of all required regulatory approvals to enable Medicare reimbursement for its CARE oral medical devices on Tuesday.
Vivos reported its fourth-quarter financial results at the end of March. The company reported quarterly losses of $3.05 per share which missed the analyst consensus estimate of $1.91 by 59.69% and quarterly sales of $3.248 million which also missed the analyst estimate.
Related News: What’s Going On With SoFi Technologies Stock?
How To Buy VVOS Stock:
By now you're likely curious about how to participate in the market for Vivos Therapeutics – be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of Vivos Therapeutics, which is trading at $2.81 as of publishing time, $100 would buy you 35.59 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
VVOS Price Action: According to Benzinga Pro, Vivos Therapeutics shares are down 11.6% at $2.68 at the time of publication Tuesday.
Image: Gerd Altmann from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
